Published on 18 Dec 2023 on Simply Wall St. via Yahoo Finance
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The...
Acorda Therapeutics, Inc. (NASDAQ:ACOR) shareholders are no doubt pleased to see that the share price has bounced 53% in the last month, although it is still struggling to make up recently lost ground. Looking back a bit further, it's encouraging to see the stock is up 37% in the last year.
In spite of the firm bounce in price, Acorda Therapeutics' price-to-sales (or "P/S") ratio of 0.2x might still make it look like a strong buy right now compared to the wider Biotechs industry in the United States, where around half of the companies have P/S ratios above 11.6x and even P/S above 49x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.
Check out our latest analysis for Acorda Therapeutics